NLA Recommendations & Statements

This statement provides updates on the evidence-based appropriate use of CAC scoring and makes practical recommendations to aid clinicians in primary prevention treatment decision-making in contemporary clinical practice. 

The NLA has released an official scientific statement on the use of genetic testing in the diagnosis and management of patients with dyslipidemia. The statement provides insights and guidance for health care providers seeking to further their understanding of the benefits, risks and patient preferences of genetic testing. 

The NLA has released a Clinical Perspective to provide strategies for early screening and education of the community and their healthcare providers, and offer practical prevention strategies and culturally-tailored dietary advice to lower the rates of ASCVD in this cohort.

The NLA has published a scientific statement on the use of icosapent ethyl (IPE) in statin-treated patients that is based on the results of REDUCE-IT, the cardiovascular outcomes trial that examined the effects of IPE on major adverse cardiovascular events in high or very high-risk statin-treated patients with elevated triglycerides.

The NLA has released a scientific statement that analyzes the impact of low-carbohydrate and very-low-carbohydrate diets (including ketogenic diets) on cardiometabolic risk factors and body weight. The statement offers conclusions regarding the potential benefits, risks, and evidence gaps regarding low-carbohydrate and very-lowcarbohydrate diets and emphasizes the importance of an evidence-based cardioprotective dietary pattern and active lifestyle to promote cardiovascular health.

The NLA released an official scientific statement on Lipoprotein(a) [Lp(a)] designed as a comprehensive source of guidance for medical professionals making decisions to improve the health and well-being of children and adults at risk of premature cardiovascular disease.

The NLA has released a statement paper that provides updated guidance to clinicians to help identify patient groups in whom treatment with PCSK9 monoclonal antibodies (mAbs) provides a reasonable value.

The Statin Adverse Treatment Experience (STATE) Survey : Experience of Patients Reporting Side Effects of Statin Therapy was designed to collect information in the patient’s voice to serve as a foundation for increased provider understanding of statin tolerability from the patient’s perspective in order to identify opportunities to improve adherence, medication management, clinical practices and – ultimately -- outcomes.

Presentation Slides
This  document  was  approved  by  the  American  College  of  Cardiology  Clinical  Policy  Approval  Committee,  the American Heart Association Science Advisory and Coordinating Committee, American Association of Cardiovascular and Pulmonary  Rehabilitation,  American  Academy  of  Physician  Assistants,  Association  of  Black  Cardiologists, American  College  of  Preventive  Medicine,  American  Diabetes  Association,  American  Geriatrics  Society,  American Pharmacists  Association,  American  Society  for  Preventive  Cardiology,  National  Lipid  Association,  and  Preventive Cardiovascular  Nurses  Association  in  October 2018,  and  the  American  Heart  Association  Executive  Committee  in  October 2018.